These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 12084106

  • 1. Comparative activity of linezolid against staphylococci and enterococci isolated in Italy.
    Stefani S, Mezzatesta ML, Tempera G, Debbra E, Schito AM, Nicoletti G, Marchére A.
    Clin Microbiol Infect; 2002 Jun; 8(6):368-72. PubMed ID: 12084106
    [Abstract] [Full Text] [Related]

  • 2. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
    Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW.
    Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.
    Johnson AP, Warner M, Livermore DM.
    J Antimicrob Chemother; 2002 Jul; 50(1):89-93. PubMed ID: 12096011
    [Abstract] [Full Text] [Related]

  • 4. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE, Tenover FC.
    Microb Drug Resist; 2003 Jul; 9(4):389-93. PubMed ID: 15000746
    [Abstract] [Full Text] [Related]

  • 5. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria.
    Munckhof WJ, Giles C, Turnidge JD.
    J Antimicrob Chemother; 2001 Jun; 47(6):879-83. PubMed ID: 11389123
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.
    Livermore DM, Warner M, Mushtaq S, North S, Woodford N.
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1112-4. PubMed ID: 17210773
    [Abstract] [Full Text] [Related]

  • 7. In vitro antimicrobial activity of linezolid tested against vancomycin-resistant enterococci isolated in Brazilian hospitals.
    Reis AO, Cordeiro JC, Machado AM, Sader HS.
    Braz J Infect Dis; 2001 Oct; 5(5):243-51. PubMed ID: 11779450
    [Abstract] [Full Text] [Related]

  • 8. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
    Sweeney MT, Zurenko GE.
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1902-6. PubMed ID: 12760865
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE, Smith JR, Raut A, Rybak MJ.
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [Abstract] [Full Text] [Related]

  • 10. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T, Moeck G.
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [Abstract] [Full Text] [Related]

  • 11. Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results.
    Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN.
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3817-20. PubMed ID: 27001823
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
    Tünger A, Aydemir S, Uluer S, Cilli F.
    Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
    [Abstract] [Full Text] [Related]

  • 13. Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods.
    Muller-Serieys C, Drugeon HB, Etienne J, Lascols C, Leclercq R, Nguyen J, Soussy CJ.
    Clin Microbiol Infect; 2004 Mar; 10(3):242-6. PubMed ID: 15008946
    [Abstract] [Full Text] [Related]

  • 14. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
    Metallidis S, Chatzidimitriou M, Nikolaidis P, Tsona A, Bisiklis A, Kollaras P, Tsiakiri E, Koumentaki E, Alexiou-Daniel S.
    J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
    [Abstract] [Full Text] [Related]

  • 15. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
    Drago L, Nicola L, De Vecchi E.
    Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
    [Abstract] [Full Text] [Related]

  • 16. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit.
    Johnson AP, Tysall L, Stockdale MV, Woodford N, Kaufmann ME, Warner M, Livermore DM, Asboth F, Allerberger FJ.
    Eur J Clin Microbiol Infect Dis; 2002 Oct; 21(10):751-4. PubMed ID: 12415476
    [Abstract] [Full Text] [Related]

  • 17. Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms.
    Chen H, Wu W, Ni M, Liu Y, Zhang J, Xia F, He W, Wang Q, Wang Z, Cao B, Wang H.
    Int J Antimicrob Agents; 2013 Oct; 42(4):317-21. PubMed ID: 23880167
    [Abstract] [Full Text] [Related]

  • 18. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
    Jones RN, Fritsche TR, Sader HS, Ross JE.
    Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
    [Abstract] [Full Text] [Related]

  • 19. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
    Brauers J, Kresken M, Menke A, Orland A, Weiher H, Morrissey I.
    Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
    [Abstract] [Full Text] [Related]

  • 20. The post-antibiotic effects of linezolid against Gram-positive pathogens.
    Hosgor-Limoncu M, Ermertcan S, Tasli H, Aydemir S.
    Saudi Med J; 2007 Apr; 28(4):551-4. PubMed ID: 17457476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.